<DOC>
<DOCNO>EP-0626372</DOCNO> 
<TEXT>
<INVENTION-TITLE>
2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]benzenecarboximid-amides for the treatment of glaucoma
</INVENTION-TITLE>
<CLASSIFICATIONS>C07D23354	C07D40310	A61K31415	A61P2702	C07D23300	C07D40300	A61K314174	A61K314164	A61P2706	A61K314164	A61K31415	C07D23364	C07D23356	A61K314178	A61P2700	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07D	C07D	A61K	A61P	C07D	C07D	A61K	A61K	A61P	A61K	A61K	C07D	C07D	A61K	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07D233	C07D403	A61K31	A61P27	C07D233	C07D403	A61K31	A61K31	A61P27	A61K31	A61K31	C07D233	C07D233	A61K31	A61P27	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
2-Hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]benzenecarboximidamides and their salts, processes for their preparation and ophthalmic compositions containing them. These new compounds correspond to the general formula: 
<
IMAGE
>
  in which     R1 = hydrogen or C1-4 alkyl;   R2 = hydrogen, hydroxyl, amino or C1-4 alkyl;   R3 = hydrogen; or   R2 and R3 = -CH2-CH2-.   These are new compounds which are capable of lowering intraocular pressure and which can be used in the treatment and prevention of glaucoma.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
Substituted 2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-benzenecarboximidamides,

their optical isomers and
their racemic mixtures corresponding to the general

formula


in which

R
1
represents a hydrogen atom or an alkyl
radical having 1 to 4 carbon atoms;
R
2
represents a hydrogen atom, a hydroxyl
group, an amino group or an alkyl radical

having 1 to 4 carbon atoms;
R
3
represents a hydrogen atom, or
R
2
 and R
3
taken together represent the -CH
2
-CH
2
- group,

as well as their addition salts of ophthalmologically
acceptable non-toxic acids.
Substituted 2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-benzenecarboximidamides

according to claim 1,
characterized in that it concerns 2-hydroxy-3-(1H-imidazol-4-ylmethyl)-benzenecarboximidamide

and its
addition salts of ophthalmologically acceptable

non-toxic acids.
Substituted 2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-benzenecarboximidamides

according to claim 1,
characterized in that it concerns N,2-dihydroxy-3-(1H-imidazol-4-ylmethyl)-benzenecarboximidamide

and its 
addition salts of ophthalmologically acceptable

non-toxic acids.
Substituted 2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-benzenecarboximidamides

according to claim 1,
characterized in that it concerns 2-hydroxy-3-(1H-imidazol-4-ylmethyl)-N-methyl-benzenecarboximidamide

and its addition salts of ophthalmologically
acceptable non-toxic acids.
Substituted 2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-benzenecarboximidamides

according to claim 1,
characterized in that it concerns 2-hydroxy-3-[1-(1H-imidazol-4-yl)ethyl]
-benzenecarboximidamide
and its

addition salts of ophthalmologically acceptable
non-toxic acids.
Substituted 2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-benzenecarboximidamides

according to claim 1,
characterized in that it concerns (+)-2-hydroxy-3-[1-(1H-imidazol-4-yl)ethyl]
-benzenecarboximidamide
and

its addition salts of ophthalmologically acceptable
non-toxic acids.
Substituted 2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-benzenecarboximidamides

according to claim 1,
characterized in that it concerns (-)-2-hydroxy-3-[1-(1H-imidazol-4-yl)ethyl]
-benzenecarboximidamide
and

its addition salts of ophthalmologically acceptable
non-toxic acids.
Substituted 2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-benzenecarboximidamides

according to claim 1,
characterized in that it concerns 2-(4,5-dihydro-1H-imidazol-2-yl)-6-(1H-imidazol-4-ylmethyl)-phenol

and
its addition salts of ophthalmologically acceptable

non-toxic acids. 
Substituted 2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-benzenecarboximidamides

according to claim 1,
characterized in that it concerns 2-hydroxy-3-(1H-imidazol-4-ylmethyl)-N-(1-methylethyl)-benzenecarboximidamide and its addition salts of

ophthalmologically acceptable non-toxic acids.
Substituted 2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-benzenecarboximidamides

according to claim 1,
characterized in that it concerns the hydrazide of 2-hydroxy-3-(1H-imidazol-4-ylmethyl]
-benzenecarboximidic
acid and its addition salts of ophthalmologically

acceptable non-toxic acids.
Method for preparing substituted 2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-benzenecarboximidamides

and their
salts as defined in claim 1, characterized in that:


a)

(1) a 2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-benzonitrile

of formula


in which R
1
 has the meaning given in claim 1, is
reacted with an alkanol having 1 to 4 carbon

atoms in the presence of gaseous hydrochloric
acid;
(2) the alkyl 2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-benzenecarboximidate

so obtained, of
formula


 
in which R
1
 has the meaning given in claim 1 and
alk represents an alkyl radical having 1 to 4

carbon atoms, is then reacted with one of the
enantiomers of α-methylbenzylamine; and
(3) the 2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-N-α-methylbenzyl-benzenecarboximidamide

thus obtained of formula


in which R
1
 has the meaning given in claim 1, is
finally reacted with a nitrogen-containing

compound of the formula R
2
NH
2
 (V) in which R
2

represents a hydrogen atom, a hydroxyl group, an
amino group or an alkyl radical having 1 to 4

carbon atoms when R
3
 is hydrogen or with
ethylenediamine (VI) when R
2
 and R
3
 taken together
represent the -CH
2
-CH
2
- group, and when it is
desired to obtain a compound of formula 1 in the

form of an optical isomer, the diastereoisomeric
N-α-methylbenzylated derivatives of formula IV,

in which R
1
 represents an alkyl radical having 1
to 4 carbon atoms, are first of all separated; or
b) an alkyl 2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-benzenecarboximidate

of formula III obtained in
the manner described in item a) above is reacted

with a nitrogen-containing compound of the
formula R
2
NH
2
 (V) in which R
2
 represents a
hydrogen atom, a hydroxyl group, an amino group

or an alkyl radical having 1 to 4 carbon atoms
when R
3
 is hydrogen or with ethylenediamine (VI)
when R
2
 and R
3
 taken together represent the -CH
2
-CH
2
- group; or 
c) in order to prepare the 2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-benzenecarboximidamides

corresponding to the general formula 1 in which
R
2
 represents a hydroxyl group and R
3
 represents a
hydrogen atom, hydroxylamine is reacted with a 2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl)]
-benzonitrile of formula


in which R
1
 has the meaning given in claim 1; or
d) in order to prepare the 2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-benzenecarboximidamides

corresponding to the general formula 1 in which
R
1
 represents an alkyl radical having 1 to 4
carbon atoms, and R
2
 and R
3
 both represent a
hydrogen atom, in the form of their optical

isomers, the diastereoisomeric 2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-N-α-methylbenzyl-benzenecarboximidamides of formula IV obtained in

the manner described in item a) above are
separated and the α-methylbenzyl group is then

eliminated from each diastereoisomer thus
separated, by hydrolysis by means of concentrated

hydrochloric acid at a temperature of between

80°C and 110°C; and
e) in that the 2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-benzenecarboximidamides

of formula I
thus obtained are optionally converted into their

addition salts of ophthalmologically acceptable
non-toxic acids.
2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-benzenecarboximidamides

according to any one of claims
1 to 10 or one of their addition salts of

ophthalmologically acceptable non-toxic acids for use
in the prevention and treatment of glaucoma.
Ophthalmic compositions for reducing the intra-ocular
pressure containing an effective quantity of one or

more 2-hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-benzenecarboximidamides

according to any one of claims
1 to 10 or of one of their addition salts of

ophthalmologically acceptable non-toxic acids, in
association with one or more solid or liquid

ophthalmologically non-toxic excipients.
</CLAIMS>
</TEXT>
</DOC>
